tirzepatide and retinopathy Molecular mechanisms underpinning activity the Study: Tirzepatide Lowers Risk of

Now, semaglutide (under the brand name Wegovy) is FDA approved for weight loss

"For many people with type 2 diabetes, it is a struggle to achieve both A1C control and weight loss, since obesity has historically been harder to treat for those with type 2 diabetes," Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said in a press release

Just under 10 percent are categorized as severely obese, a group that has been growing quickly across the country

Dose-Response Relationship Clinical data shows clear progression between Retatrutide doses and outcomes

Potential areas of expansion include: Cardiovascular outcomes: A dedicated CVOT, if not already required as a post-marketing commitment, would evaluate whether orforglipron reduces MACE in patients with established cardiovascular disease or high cardiovascular risk, following the precedent set by the SELECT trial for semaglutide